Stuart Fischer, MD, FACC, FACP, FSCAI, CCDS

Dr. Stuart Fischer joined Los Alamitos Cardiovascular in 1985 and is co-founder of the medical practice. Dr. Fischer is board certified in Interventional Cardiology, Cardiovascular Disease and Internal Medicine.

Dr. Stuart Fischer"Patients, not the doctors, are the most important part of our practice. We strive to give the best care and advice, so our patients can always make informed decisions regarding their care..."

On Medicine
Medicine is in a constant state of change. Government regulations, insurance providers are only some of the difficulties with Medicine today. One constant in all of this turmoil, is Los Alamitos Cardiovascular's continued commitment to our patient's care.

On Los Alamitos Cardiovascular
We are 6 unique cardiologists who have come together to form a cohesive group, able to provide excellent, comprehensive cardiovascular and endovascular care for our patients.

On My Specialty
Cardiovascular and Endovascular care has seen tremendous growth, and staying ahead of the curve in order to provide state of the art care for our patients is our mission.

Dr. Stuart Fischer's Curriculum Vitae

Printable VersionView Printable CV
Specialties: Cardiovascular Diseases, Interventional Cardiology, Endovascular Diseases
Board Certifications:
  • Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology
    National Board of Physicians and Surgeons
  • Certified in Interventional Cardiology
    American Board of Internal Medicine
    1999  (Recertification 2011 – 2021)
  • Certified Cardiac Device Specialist (CCDS)
    International Board of Heart Rhythm Examiners (IBHRE)
    Certification Examination for Competency in Cardiac Rhythm Device Therapy for the Physician
  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
  • Certified in Internal Medicine
    American Board of Internal Medicine

Current Hospital Appointments:

  • Los Alamitos Medical Center
    Active staff since April 1985

    3751 Katella Avenue
    Los Alamitos, California 90720

  • MemorialCare Health System
    Long Beach Memorial Medical Center
    Active staff since December 1985

    2801 Atlantic Avenue
    Long Beach, California 90801

Other Hospital Affiliations:

  • Memorial Heart Institute
    Founding Fellow, January 1987

  • University of California, Irvine
    Courtesy Staff since April 1986
Committees: Los Alamitos Medical Center
  • Chairman, Credentials Committee, 1996 – Present
  • Member, Governing Board: 1994 – 2001, 2004 – Present
  • Chief of Staff, 1994 – 1995
  • Vice Chief of Staff, 1993
  • Chairman, Quality Assurance Committee, 1993
  • Chairman, Critical Care Committee, 1989
  • Chairman, Department of Medicine, 1990 – 1992
  • Member, Executive Committee, 1989 – Present
  • Director Cardiac Catheterization Lab, 1989 – 2013
  • Director, Pacemaker Clinic, 1985 – 2007
  • Director, Echocardiography Lab, 1985 – 1997
  • Secretary-Treasurer Medical Staff, 1992
Long Beach Memorial Medical Center
  • Member, Interventional Cardiology Sub-Committee, 1997 – Present
  • Member, Cardiology Credentials and QA Committee, 1996 – Present
Lakewood Regional Medical Center
  • Member, Executive Committee: 2000 – 2001, 2004 – 2007
  • Director, Cardiac Catheterization Lab, 2002 – 2005
Professional Societies:
  • American College of Cardiology (FACC)
  • American College of Physicians (FACP)
  • The Society for Cardiac Angiography and Interventions (FSCAI)
  • Heart Rhythm Society-IBHRE CCDS
  • The Society of Geriatric Cardiology (FSGC)
  • Co-Director Interventional Fellowship Program
    University of California, Irvine/Long Beach Memorial Hospital
    July 2000 – Present

  • Assistant Clinical Professor of Medicine
    University of California, Irvine
    July 1989 – Present
Work History:
  • Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc.
    Los Alamitos, California
    1985 – Present

  • Fischer Mangold Group
    Emergency Medicine
    St. Francis - St. George Hospital
    Cincinnati, Ohio
    1982 – 1983

  • Medical Health Service
    Staffing Three Cincinnati ER's(Part Time)
    Cincinnati, Ohio
    1980 – 1983

  • Bethesda Hospital
    Critical Care Physician (Part Time)
    Cincinnati, Ohio
    1981 – 1983

Professional Recognition:
  • American Medical Association Physician’s Recognition Award in Continuing Medical Education
    January 2008 – January 2011

  • Sarah Lipson Seigal Memorial Award for Research
  • Kumar P, Agarwal P, VanNatta B, Shandling A, Fischer S, McAtee P, Messenger J. “Clinical evaluation of ThinLine II (models 430-25 and 438-25 Intermedics) bipolar pacing leads.” PACE. 1999; 22 Part II 869.

  • Dabestani A, Takenaka K, Allen B, Gardin J, Fischer S, Russell D, Henry W. “Effects of Spontaneous Respiration on Diastolic Left Ventricular Filling Assessed by Pulsed Doppler Echocardiography.” Am J Cardiol. 1988; 61:1356-1358.
  • Cardiovascular Diseases Fellowship
    University of California, Irvine
    Division of Cardiology
    Orange, California
    Walter L. Henry, MD, Chief
    1983 – 1985

  • Internal Medicine Residency
    University of Cincinnati Medical Center
    Department of Internal Medicine
    Cincinnati, Ohio
    Martin Goldberg, MD, Chair
    1980 – 1982

  • Straight Medical Internship
    University of Cincinnati Medical Center

    Department of Internal Medicine
    Cincinnati, Ohio
    Martin Goldberg, MD, Chair
    1979 – 1980

  • Medical Education
    Cornell University Medical College

    New York, New York
    1977 – 1979

  • Medical Education
    Universita di Sassari
    Faculta di Medicinav
    Sassari, Italy
    1973 – 1977

  • Undergraduate Education
    Brooklyn College

    Brooklyn, New York
    BS, Biology, 1969 – 1973
Clinical Expertise:

Non-Invasive Cardiology:
Echocardiography – TEE, Dobutamine and Stress Echo.

Invasive-Interventional Cardiovascular and Endovascular Diseases:
Catheterization, PTCA, Atherectomy, Stents, Laser Atherectomy, VBT, Pacing, Peripheral Vascular Disease, Peripheral Interventions, and Current Level II certification for performing and interpreting MDCTA

Research Interests:
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Sub-Investigator | 2017
    Sponsor: Amgen

  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Principal Investigator | 2017
    Sponsor: Novartis

  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Sub-Investigator | 2016 – Present
    Sponsor: CVRx, Inc.

  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Sub-Investigator | 2016
    Sponsor: Gilead/ICON

  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Principal Investigator | 2015 – Present
    Sponsor: AstraZeneca
    NCT01991795 |

  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015
    Sponsor: Amgen, Evidera

  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Sub-Investigator | 2013 – Present
    Sponsor: AstraZeneca
    NCT01730534 |

  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.
    Principal Investigator | 2013 – Present
    Sponsor: Sanofi
    NCT01663402 |

  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Principal Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
    NCT01755052 |

  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Sub-Investigator | 2013
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson

  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Sub-Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
    NCT0169580 |

  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Sub-Investigator | 2013 – Present
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
    NCT01594333 |

  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
    Sub-Investigator | 2012
    Sponsor: Alere San Diego

  • Mission® PT Coagulation Monitoring System Clinical Study.
    Sub-Investigator | 2012
    Sponsor: ACON Laboratories, INC.

  • The "BRIDGE" Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Sub-Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
    NCT00786474 |

  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Sub-Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
    NCT01468701 |

  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
    NCT01062126 |

  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Sub-Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
    NCT01174550 |

  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Sub-Investigator | 2010 – Present
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 |
    NCT01701817 |

  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00837798 |

  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00418314 |

  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
    Sub-Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development
    NCT00781391 |

  • Phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of Dalcetrapib on lipids, lipoproteins,apolipoproteins and markers of CV Risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (Dal-ACUTE).
    Sub-Investigator | 2008 – 2012
    Sponsor: F. Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc. , Roche Global Development.
    NCT01323153 |

  • Multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in treating iron deficiency anemia in subjects who are not dialysis dependent.
    Sub-Investigator | 2007 – 2009
    Sponsor: Luitpold Pharmaceuticals, Inc.
    NCT00704028 |

  • Echocardiographic Assessment of Mitral Stenosis, Two-Dimensional Echocardiography versus Doppler Pressure Half Time
    Exercise Echocardiography in Coronary Artery Disease
    Doppler Mitral Flow in Various Pathologic States
    Thin-Line Bi-Polar Pacemaker Leads.
    Department of Physiology, Albany Medical College
    Sponsor:  Intermedics

California, New York, Ohio

Local Organizations:

Rotary 1986 – 1989